End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6265 USD | -4.56% | -17.02% | -97.69% |
May. 21 | Earnings Flash (SBFM) SUNSHINE BIOPHARMA Posts Q1 Revenue $7.5M | MT |
May. 20 | Sunshine Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 44.94M | Sales 2025 * | 100M | Capitalization | 11.87M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | 11M | EV / Sales 2024 * | 0.26 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.12 x |
P/E ratio 2024 * |
-0.63
x | P/E ratio 2025 * |
0.01
x | Employees | 44 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.5% |
1 day | -4.56% | ||
1 week | -17.02% | ||
1 month | -27.17% | ||
3 months | -88.69% | ||
6 months | -97.84% | ||
Current year | -97.69% |
Managers | Title | Age | Since |
---|---|---|---|
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
Marc Beaudoin
COO | Chief Operating Officer | - | Jan. 24 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Natan
BRD | Director/Board Member | 70 | 22-01-31 |
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.6265 | -4.56% | 954,061 |
24-05-30 | 0.6564 | +3.50% | 2,335,085 |
24-05-29 | 0.6342 | -8.76% | 2,096,743 |
24-05-28 | 0.6951 | -7.93% | 1,959,315 |
24-05-24 | 0.755 | +1.75% | 907,781 |
End-of-day quote Nasdaq, May 30, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.69% | 11.87M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- SBFM Stock